Core Insights - Boston Scientific (BSX) shares have increased by 7% over the past 30 days, outperforming its industry and major competitors [1][8] - The company reported strong Q3 2025 performance, with operational sales and adjusted EPS each growing by 19% [3][8] - BSX has agreed to acquire Nalu Medical to enhance its chronic pain management portfolio [12][19] Performance Overview - BSX's stock performance has surpassed the industry's 0.9% gains, the Medical sector's 5.6% growth, and the S&P 500's 3% rise [1] - The stock closed at $104.98, just 4.1% below its 52-week high [3] - The company's Electrophysiology unit experienced a 63% year-over-year sales growth in Q3, driven by the Farapulse system [9] Business Segments - The Cardiovascular and MedSurg businesses contributed significantly to BSX's strong Q3 results [3][8] - The WATCHMAN business sales grew by 35% in Q3, with expectations for increased adoption of concomitant procedures [10] - Asia-Pacific sales grew by 17%, with strong performances in Japan and China [11] Strategic Initiatives - BSX is acquiring Nalu Medical for approximately $533 million to expand its neuromodulation offerings [12][13] - The company has been a strategic investor in Nalu since 2017 and expects Nalu to generate over $60 million in sales in 2025 [13] - BSX's revised 2025 outlook suggests approximately 20% net sales growth, exceeding previous guidance [16] Valuation Metrics - BSX shares are trading at a forward five-year price-to-sales (P/S) ratio of 7.08X, above the industry average [17]

Core Insights - Hologic and Boston Scientific are prominent U.S. MedTech companies, with Hologic focusing on women's health and Boston Scientific on less-invasive medical devices [1][8] - Hologic's market cap is $14.94 billion, while Boston Scientific's is significantly larger at $155.90 billion [1] Hologic Overview - Hologic's fiscal 2025 third-quarter performance indicates recovery and growth, aided by a new leadership team and strategy in Breast Health [3] - The company is launching innovative products like Genius AI Detection PRO and the Envision mammography platform [3] - U.S. Molecular Diagnostics grew 7.3% year-over-year, driven by specific assay portfolios [4] - The Genius Digital Diagnostics System is gaining traction globally, addressing labor shortages in cervical cancer screening [5] - Hologic's strong balance sheet supports capital allocation strategies, including share repurchases and M&A activities [6] - The company has reduced anticipated tariff impacts for fiscal 2026, but still faces macroeconomic challenges [7] Boston Scientific Overview - Boston Scientific's Cardiovascular segment showed strong performance, with Electrophysiology sales increasing by 91% in Q2 2025 [8][9] - The company is focusing on strategic M&A and high-growth areas, acquiring SoniVie and Intera Oncology [10] - Emerging markets delivered 12.1% year-over-year operational sales growth despite geopolitical challenges [10] - The MedSurg segment, particularly Endoscopy, showed strength with notable growth in key products [11] - Urology sales grew 28% operationally, supported by acquisitions and product innovations [12] - Boston Scientific has cut its 2025 tariff impact forecast to approximately $100 million [13] Financial Performance and Valuation - Year-to-date, Hologic shares have decreased by 5.4%, while Boston Scientific shares have increased by 18.8% [16] - Hologic's forward price-to-sales ratio is 3.58, slightly above its median, while Boston Scientific's is 4.14, below its median [17] - Hologic's EPS for fiscal 2025 is estimated to grow by 3.7% to $4.23, while Boston Scientific's EPS is projected to improve by 18.7% to $2.98 [19][21] Conclusion - Boston Scientific shows strong momentum in its segments and favorable earnings projections, making it a more compelling investment opportunity compared to Hologic, which is also on a growth trajectory but faces economic headwinds [22]